Levocetirizine
- Generic Name
- Levocetirizine
- Brand Names
- Xyzal
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O3
- CAS Number
- 130018-77-8
- Unique Ingredient Identifier
- 6U5EA9RT2O
- Background
Levocetirizine is a selective histamine H antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H receptor than cetirizine.
Levocetirizine was granted FDA approval in 1995.
- Indication
Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It is also used over the counter for a variety of mild allergy symptoms.
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 200
- Registration Number
- NCT00160537
ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- UCB S.A. - Pharma Sector
- Target Recruit Count
- 62
- Registration Number
- NCT00160680
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 207
- Registration Number
- NCT00160563
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 514
- Registration Number
- NCT00152464
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath